Hansa Biopharma AB (ST:HNSA) — Stock Price
Hansa Biopharma AB (ST:HNSA) is currently trading at Skr39.62 SEK, down 2.70% today. Over the past 52 weeks, shares have ranged between Skr24.88 and Skr42.74. This page tracks Hansa Biopharma AB's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Hansa Biopharma AB.
Hansa Biopharma AB (HNSA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Hansa Biopharma AB's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.
Hansa Biopharma AB Income Statement — Revenue, Profit & Earnings by Year
Hansa Biopharma AB's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | Skr171.32 Million | Skr134.09 Million | Skr154.53 Million | Skr33.88 Million | Skr6.10 Million |
| Cost of Revenue | Skr83.55 Million | Skr63.14 Million | Skr38.48 Million | Skr15.43 Million | Skr997.00K |
| Gross Profit | Skr87.76 Million | Skr70.95 Million | Skr116.05 Million | Skr18.45 Million | Skr5.10 Million |
| Research & Development | Skr375.72 Million | Skr411.33 Million | Skr346.24 Million | Skr230.76 Million | Skr227.19 Million |
| SG&A | Skr343.77 Million | Skr450.49 Million | Skr337.86 Million | Skr327.27 Million | Skr202.99 Million |
| Total Operating Expenses | Skr725.64 Million | Skr859.45 Million | Skr692.17 Million | Skr558.03 Million | Skr430.18 Million |
| Operating Income | Skr-637.88 Million | Skr-788.50 Million | Skr-576.12 Million | Skr-539.58 Million | Skr-425.08 Million |
| EBITDA | Skr-642.07 Million | Skr-714.55 Million | Skr-554.26 Million | Skr-538.83 Million | Skr-413.08 Million |
| EBIT | Skr-670.13 Million | Skr-725.29 Million | Skr-566.31 Million | Skr-547.44 Million | Skr-420.64 Million |
| Interest Expense | Skr134.08 Million | Skr105.52 Million | Skr43.67 Million | Skr694.00K | Skr257.00K |
| Income Before Tax | Skr-804.21 Million | Skr-830.81 Million | Skr-609.98 Million | Skr-548.13 Million | Skr-420.89 Million |
| Income Tax Expense | Skr3.03 Million | Skr908.00K | Skr1.16 Million | Skr152.00K | Skr-40.00K |
| Net Income | Skr-807.24 Million | Skr-831.72 Million | Skr-611.13 Million | Skr-548.28 Million | Skr-420.85 Million |
Hansa Biopharma AB Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Hansa Biopharma AB's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | Skr800.64 Million | Skr1.02 Billion | Skr1.69 Billion | Skr1.01 Billion | Skr1.43 Billion |
| Total Current Assets | Skr585.43 Million | Skr855.15 Million | Skr1.60 Billion | Skr942.34 Million | Skr1.39 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | Skr0.00 | Skr237.62 Million | Skr238.14 Million |
| Net Receivables | Skr146.33 Million | Skr78.03 Million | Skr65.01 Million | Skr20.96 Million | Skr6.94 Million |
| Inventory | Skr2.61 Million | Skr1.51 Million | Skr973.00K | Skr242.00K | Skr98.00K |
| Property, Plant & Equipment | Skr17.88 Million | Skr27.07 Million | Skr35.84 Million | Skr41.70 Million | Skr9.70 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Skr1.39 Billion | Skr1.19 Billion | Skr1.08 Billion | Skr255.24 Million | Skr192.37 Million |
| Total Current Liabilities | Skr255.69 Million | Skr320.99 Million | Skr264.71 Million | Skr171.22 Million | Skr114.20 Million |
| Long-term Debt | Skr1.06 Billion | Skr844.90 Million | Skr762.60 Million | Skr722.00K | Skr663.00K |
| Net Debt | Skr673.73 Million | Skr134.71 Million | Skr-705.09 Million | Skr-615.96 Million | Skr-1.13 Billion |
| Total Stockholder Equity | Skr-589.83 Million | Skr-167.88 Million | Skr602.91 Million | Skr757.57 Million | Skr1.24 Billion |
| Retained Earnings | Skr-4.11 Billion | Skr-3.30 Billion | Skr-2.47 Billion | Skr-1.86 Billion | Skr-1.31 Billion |
Hansa Biopharma AB Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Hansa Biopharma AB generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | Skr-674.88 Million | Skr-755.65 Million | Skr-502.73 Million | Skr-481.17 Million | Skr-290.27 Million |
| Capital Expenditures | Skr116.00K | Skr284.00K | Skr3.33 Million | Skr2.40 Million | Skr294.00K |
| Free Cash Flow | Skr-675.00 Million | Skr-755.94 Million | Skr-506.06 Million | Skr-483.57 Million | Skr-290.57 Million |
| Investing Cash Flow | Skr-116.00K | Skr-284.00K | Skr229.31 Million | Skr-2.40 Million | Skr182.53 Million |
| Financing Cash Flow | Skr346.81 Million | Skr-7.54 Million | Skr1.12 Billion | Skr-4.86 Million | Skr1.07 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | Skr60.64 Million | Skr58.23 Million | Skr56.62 Million | Skr43.35 Million |
| Depreciation | Skr28.06 Million | Skr19.79 Million | Skr12.05 Million | Skr8.61 Million | Skr7.67 Million |
| Change in Cash | Skr-326.78 Million | Skr-764.12 Million | Skr844.84 Million | Skr-488.02 Million | Skr957.66 Million |
Hansa Biopharma AB Earnings History — EPS Actual vs. Analyst Estimates
Track Hansa Biopharma AB's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 22, 2026 | — | — | — |
| Feb 05, 2026 | — | -1.71 | — |
| Oct 29, 2025 | -1.75 | -1.85 | +5.41% |
| Jul 17, 2025 | -1.69 | -1.65 | -2.42% |
| Apr 24, 2025 | -0.55 | -2.67 | +79.40% |
| Feb 06, 2025 | -4.08 | -1.98 | -106.06% |
| Oct 17, 2024 | -1.53 | -2.42 | +36.78% |
| Jul 18, 2024 | -3.30 | -2.78 | -18.71% |